Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.
about
DNA immunization as a technology platform for monoclonal antibody inductionRabbit Anti-HIV-1 Monoclonal Antibodies Raised by Immunization Can Mimic the Antigen-Binding Modes of Antibodies Derived from HIV-1-Infected HumansEffect of vaccine administration modality on immunogenicity and efficacy.Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studiesCo-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cellsElicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoproteinSerum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.Mucosal vaccines against respiratory syncytial virusBoosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccinationHIV vaccines: lessons learned and the way forward.A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates.Serum neutralizing activities from a Beijing homosexual male cohort infected with different subtypes of HIV-1 in China.Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine.Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses.Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodiesTwo closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates.A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections.Clinical applications of DNA vaccines: current progress.SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.Pilot Study on the Use of DNA Priming Immunization to Enhance Y. pestis LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine.Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost.Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.Immunization with Brugia malayi Myosin as Heterologous DNA Prime Protein Boost Induces Protective Immunity against B. malayi Infection in Mastomys coucha.Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.DNA prime-protein boost using subtype consensus Env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China.Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates.Reduced MyD88 dependency of ISCOMATRIX™ adjuvant in a DNA prime-protein boost HIV vaccine.Polyvalent AIDS vaccines.Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates.DNA immunization.Improvement of antibody responses by HIV envelope DNA and protein co-immunization.The strategic use of novel smallpox vaccines in the post-eradication world.Selected approaches for increasing HIV DNA vaccine immunogenicity in vivoImproved outlook on HIV-1 prevention and vaccine development.New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines.
P2860
Q26751432-22682031-42BC-4F4D-9152-A5B8FCF4E3A1Q27679123-2066CAA1-DA65-420C-AAE1-06005CB911A2Q27692376-64C8B9EC-1E89-4D99-94A5-2BF1A6D6DA24Q28730904-FB84A0F4-E9B9-490C-B827-C45310A7B8F9Q28732043-0601765E-FC1E-47A6-A8CE-A1358A91AB8DQ28732438-02833C50-8BC4-417F-B4AA-2A60F783858FQ31138173-57806D41-3362-4091-8F1A-CCCA293F48DCQ33837530-82D825ED-7486-456E-A571-FB2074A223C9Q33955745-71490DEC-1550-442F-AAAB-AFBD2F6AE442Q34291205-4E1D80E7-D650-411A-BAAE-AAA4971C1CDAQ34342558-4BAD3AE0-CB8F-45CF-B7A1-3D4B91745A19Q34444535-66A086A0-2FCD-476D-836A-717CC89DAA11Q34456367-69A42131-FDE5-4C2F-9CB1-8F0FCBF3538EQ34487821-90C74405-81D6-444A-AE33-06B279F8F551Q34557185-39F90B9D-0C70-4B15-8DFA-CF5D674FFC7FQ34982715-519ED760-A1CE-4180-88F5-80B1C3365E54Q35076664-8A09EF8C-38F2-46E5-BE81-413945FAE207Q35076748-C45BA883-C4DA-4282-966C-0D3AD0BB0078Q35193959-F54325BD-86F2-4F2B-AEC4-8E479CE5BA8FQ35452312-F8C6E539-D80F-4859-A8DB-8FC5CE20892DQ35754196-41573752-BE87-43E4-9273-CAF17EB8668FQ35826610-F9D177C0-8E85-43EB-9B9C-EE7E66788889Q35883032-FF0D1682-D5FA-4332-AF49-062944CA42CCQ35883997-3D21788F-3C54-440F-9BEA-AA0F4C126A74Q36119504-91601D99-B010-4542-A4D0-0106B7529534Q36187270-FFC16505-FC70-4106-9C9E-4F1F64F48D02Q36249053-8F2146A6-CAEF-4A8E-AAD0-949E932B83D2Q36694841-0BFE9E98-206E-4D86-B440-61A860775C55Q36694846-EE1990C6-F2B2-40F8-B9BD-4BB608E50004Q36977750-7CDA25D0-5227-4588-9895-274F43552FE7Q37094429-A9B4A887-C01A-4D8C-B38F-DB561C22CD53Q37252966-E5B79A71-3A8F-4192-B0E8-5AB161C5A1D9Q37336704-5A6E35D2-F7B7-4D67-940A-5D21CE8285CBQ37576264-0D8211A6-E433-4C84-9EE8-731C099B8579Q37588371-5C794337-4B67-4E08-A53E-1DC0C6728A7BQ37909421-13DE9DA1-7248-452C-9D70-6982F57CA325Q37996192-0121EACB-B6CD-4F72-90B0-BB46CD490E42Q38009870-04888585-D143-48A9-92CD-2BB40546D05BQ38748193-898B1CD5-AFA9-48FC-B8B2-295B1EC9C473Q40294097-EA7D0B0A-9858-4E9A-9159-5457CBBD1DD0
P2860
Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Antibody responses elicited th ...... nctional activity and avidity.
@ast
Antibody responses elicited th ...... nctional activity and avidity.
@en
type
label
Antibody responses elicited th ...... nctional activity and avidity.
@ast
Antibody responses elicited th ...... nctional activity and avidity.
@en
prefLabel
Antibody responses elicited th ...... nctional activity and avidity.
@ast
Antibody responses elicited th ...... nctional activity and avidity.
@en
P2093
P2860
P1433
P1476
Antibody responses elicited th ...... unctional activity and avidity
@en
P2093
Anthony Hackett
James Arthos
Michael Vaine
Shixia Wang
P2860
P304
P356
10.1016/J.VACCINE.2010.02.006
P407
P50
P577
2010-02-17T00:00:00Z